Multiple Sclerosis Journal - Experimental Translational and Clinical · 2015 · 52 citations · 23 references
Health ProfessionsRehabilitation MedicineMobility RehabilitationPsychometricsRehabilitationGait AssessmentGait ImpairmentMobility AssessmentMultiple SclerosisMultiple Sclerosis PharmacotherapyWalking PerformanceEuroqol Five DimensionsExploratory Clinical TrialsMobility Outcome MeasurementMultiple Sclerosis MobilityPatient-reported Outcome MeasurementWalkingWalking AbilityWalking Scores
BACKGROUND: The 12-question Multiple Sclerosis Walking Scale (MSWS-12v1) is a widely-used patient-reported outcome (PRO) measure of walking ability in multiple sclerosis (MS). OBJECTIVE: To estimate the magnitude of an important change in MSWS-12v1 scores for the interpretation of meaningful subject-level improvements across a 6-month trial of MS patients with walking disability. METHODS: MOBILE was a 6-month exploratory study assessing fampridine's effect on walking ability in 132 people with MS. Three PRO measures assessed walking ability: MSWS-12v1, EuroQol 5-Dimension-5 Level (EQ-5D-5L) mobility question, and a patient global impression of change (PGIC) in overall walking ability. Pre-specified anchor- and distribution-based analyses estimated the MSWS-12v1 change scores representing an important change for participants. Results were triangulated to propose a single best value indicating meaningful improvement. RESULTS: Using baseline to week 2 through week 24 change scores, anchor-based analyses demonstrated mean and median improvements of 5.2-6.6 (PGIC) and 9.7-13.4 (EQ-5D-5L mobility) points on the MSWS-12v1, indicating meaningful improvements. The distribution-based estimate was 6.8 points. Triangulation across the results suggested an 8-point reduction in MSWS-12v1 score represents an important subject-level change in these participants. CONCLUSION: In similar MS clinical trials, an 8-point improvement on the MSWS-12v1 is a reasonable estimate of meaningful improvement in walking ability.
23
EuroQol - a new facility for the measurement of health-related quality of life
Health Policy · 1990 · 15.8K citations
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Michael Herdman, Claire Gudex, Andrew Lloyd et al. · Quality of Life Research · 2011 · 10K citations · Full text
Roman Jaeschke, Joel Singer, Gordon Guyatt · Controlled Clinical Trials · 1989 · 4.9K citations